Search - tctmd.com

Displaying 21 - 25 of 25

Sort: Relevancy | Date

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

初期研究显示利伐沙班拮抗剂安全、有效

December 30, 2013

News Daily News

Rivaroxaban Antidote Appears Safe, Effective in Early Study

December 30, 2013

News Daily News

El Antídoto de Rivaroxaban parece Seguro y Eficaz en un Estudio Preliminar

December 30, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.